Methergin

Methylergometrine maleate, the active ingredient in Methergin, is an ergot alkaloid presented as a sterile injectable solution for intramuscular and intravenous use. It is employed to prevent and treat postpartum hemorrhage and to control uterine atony in the obstetric setting.

GNH USA supplies Methergin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Methergin is an ergot alkaloid uterotonic used in obstetrics to manage bleeding and promote uterine contraction.

- Postpartum hemorrhage: helps prevent and treat excessive bleeding after delivery. - Uterine atony: induces sustained uterine muscle contraction to stop bleeding. - Cesarean section bleeding: assists in controlling intra‑operative uterine bleeding.

Methergin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Headache: transient cranial discomfort. - Hypertension: temporary rise in blood pressure. - Flushing: warm sensation with skin reddening.

Serious or Rare Side Effects: - Coronary artery spasm: severe chest pain requiring urgent care. - Myocardial ischemia: reduced heart blood flow, potentially life‑threatening. - Pulmonary edema: fluid accumulation in lungs. - Anaphylaxis: rapid allergic reaction with airway compromise.

Before administering Methergin, clinicians should consider several safety measures.

- Blood pressure monitoring: observe for hypertension during and after dosing. - Cardiovascular assessment: evaluate history of heart disease before use. - Caution in hypertension: avoid high doses in patients with uncontrolled high blood pressure. - Hypersensitivity check: discontinue if signs of allergic reaction appear. - Obstetric supervision: ensure administration under qualified obstetric care. - Store at controlled room temperature: keep in original container, protect from light and moisture.

Methergin can interact with other medications, requiring careful management.

Major Interactions (Avoid): - Ergotamine‑containing drugs: additive vasoconstrictive effects. - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase methylergometrine levels.

Moderate Interactions (Monitor Closely): - Alpha‑adrenergic blockers: may diminish uterotonic efficacy. - Beta‑blockers: potential for altered cardiovascular response.